Cantitate/Preț
Produs

Advances in Lymphoma Research: Cancer Treatment and Research, cartea 85

Editat de Fernando Cabanillas, M. Alma Rodriguez
en Limba Engleză Hardback – 28 feb 1997
Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third­ generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 137521 lei  6-8 săpt.
  Springer Us – 8 oct 2012 137521 lei  6-8 săpt.
Hardback (1) 138200 lei  6-8 săpt.
  Springer Us – 28 feb 1997 138200 lei  6-8 săpt.

Din seria Cancer Treatment and Research

Preț: 138200 lei

Preț vechi: 145473 lei
-5% Nou

Puncte Express: 2073

Preț estimativ în valută:
26453 27769$ 21852£

Carte tipărită la comandă

Livrare economică 30 ianuarie-13 februarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780792339298
ISBN-10: 0792339290
Pagini: 169
Ilustrații: XI, 169 p.
Dimensiuni: 155 x 235 x 13 mm
Greutate: 0.44 kg
Ediția:1996
Editura: Springer Us
Colecția Springer
Seria Cancer Treatment and Research

Locul publicării:New York, NY, United States

Public țintă

Research

Cuprins

I. New Therapeutic Advances 1.- 1. Fludarabine phosphate in lymphoma: an important new therapeutic agent.- 2. 2-Chlorodeoxyadenosine treatment of lymphoma.- II. New Histopathologic Entities.- 3. Histologic grading of nodular sclerosing Hodgkin’s disease: is it an independent prognostic factor?.- 4. Mantle cell lymphomas.- III. New Perspectives on Clinical Prognostic Parameters and Treatment.- 5. Can prognostic factors be applied in treatment selection for aggressive lymphoma patients?.- 6. Factors that influence prognosis of intermediate-grade lymphomas at relapse.- 7. High-dose chemotherapy in non-Hodgkin’s lymphoma.- IV. New Biomolecular Markers/Targets.- 8. The phenomenon of multidrug resistance in non-Hodgkin’s lymphoma.- 9. Adhesion molecules in non-Hodgkin’s lymphoma.- 10. PCR monitoring of response in patients treated with high-dose chemotherapy for low-grade lymphoma.